Right Ventricular Dysfunction in Chronic Lung Disease

Cardiology Clinics

Volumn 30, Issue 2, 2012, Pages 243-256

  Kolb, Todd M ^a   Hassoun, Paul M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chronic lung disease; Cor pulmonale; Pulmonary hypertension; Right ventricle

Indexed keywords

AMBRISENTAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOSENTAN; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; OXYGEN; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SHORT ACTING DRUG; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; THEOPHYLLINE; UNIPROST;

ASTHMA; CARDIOVASCULAR RESPONSE; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; HEART AFTERLOAD; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTIOCYTOSIS X; HYPOXEMIA; HYPOXIA; LONG TERM CARE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG RESECTION; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MORTALITY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY;

ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; LUNG DISEASES; OXYGEN; PROGNOSIS; RESPIRATORY SYSTEM AGENTS; SURVIVAL ANALYSIS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84860382243     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2012.03.005     Document Type: Review

References (117)

1. Laennec R.T. A treatise on diseases of the chest 1821, T. and G. Underwood, London.
2. Chronic cor pulmonale: report of an expert committee. Circulation 1963, 27:594-615.
3. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S43-S54.
4. Ben Jrad I., Slimane M.L., Boujnah M.R., et al. Tunis Med 1993, 71(11):505-508. [in French].
5. Weitzenblum E., Chaouat A., Canuet M., et al. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009, 30(4):458-470.
6. Hyduk A., Croft J.B., Ayala C., et al. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ 2005, 54(5):1-28.
7. Minai O.A., Chaouat A., Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010, 137(Suppl 6):39S-51S.
8. Scharf S.M., Iqbal M., Keller C., et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002, 166(3):314-322.
9. Badesch D.B., Champion H.C., Sanchez M.A., et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S55-S66.
10. Han M.K., McLaughlin V.V., Criner G.J., et al. Pulmonary diseases and the heart. Circulation 2007, 116(25):2992-3005.
11. Hamada K., Nagai S., Tanaka S., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007, 131(3):650-656.
12. Lettieri C.J., Nathan S.D., Barnett S.D., et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006, 129(3):746-752.
13. Nathan S.D., Shlobin O.A., Ahmad S., et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007, 131(3):657-663.
14. Sajkov D., McEvoy R.D. Obstructive sleep apnea and pulmonary hypertension. Prog Cardiovasc Dis 2009, 51(5):363-370.
15. Kessler R., Chaouat A., Schinkewitch P., et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001, 120(2):369-376.
16. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1(8222):681-686.
17. Bogaard H.J., Abe K., Vonk Noordegraaf A., et al. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009, 135(3):794-804.
18. Kayar S.R., Banchero N. Myocardial capillarity in acclimation to hypoxia. Pflugers Arch 1985, 404(4):319-325.
19. Partovian C., Adnot S., Eddahibi S., et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 1998, 275(6):H1948-H1956.
20. Vonk-Noordegraaf A., Marcus J.T., Holverda S., et al. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest 2005, 127(6):1898-1903.
21. Scott K.W. A clinicopathological study of fatal chronic airways obstruction. Thorax 1976, 31(6):693-701.
22. Shivkumar K., Ravi K., Henry J.W., et al. Right ventricular dilatation, right ventricular wall thickening, and Doppler evidence of pulmonary hypertension in patients with a pure restrictive ventilatory impairment. Chest 1994, 106(6):1649-1653.
23. Bradley T.D., Rutherford R., Grossman R.F., et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985, 131(6):835-839.
24. Guidry U.C., Mendes L.A., Evans J.C., et al. Echocardiographic features of the right heart in sleep-disordered breathing: the Framingham Heart Study. Am J Respir Crit Care Med 2001, 164(6):933-938.
25. Dursunoglu N., Dursunoglu D., Kilic M. Impact of obstructive sleep apnea on right ventricular global function: sleep apnea and myocardial performance index. Respiration 2005, 72(3):278-284.
26. Vizza C.D., Lynch J.P., Ochoa L.L., et al. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998, 113(3):576-583.
27. Burghuber O.C., Bergmann H. Right-ventricular contractility in chronic obstructive pulmonary disease: a combined radionuclide and hemodynamic study. Respiration 1988, 53(1):1-12.
28. Biernacki W., Flenley D.C., Muir A.L., et al. Pulmonary hypertension and right ventricular function in patients with COPD. Chest 1988, 94(6):1169-1175.
29. Caso P., Galderisi M., Cicala S., et al. Association between myocardial right ventricular relaxation time and pulmonary arterial pressure in chronic obstructive lung disease: analysis by pulsed Doppler tissue imaging. J Am Soc Echocardiogr 2001, 14(10):970-977.
30. Huez S., Retailleau K., Unger P., et al. Right and left ventricular adaptation to hypoxia: a tissue Doppler imaging study. Am J Physiol Heart Circ Physiol 2005, 289(4):H1391-H1398.
31. Archer S., Michelakis E. The mechanism(s) of hypoxic pulmonary vasoconstriction: potassium channels, redox O(2) sensors, and controversies. News Physiol Sci 2002, 17:131-137.
32. Enson Y., Giuntini C., Lewis M.L., et al. The influence of hydrogen ion concentration and hypoxia on the pulmonary circulation. J Clin Invest 1964, 43:1146-1162.
33. Timms R.M., Khaja F.U., Williams G.W. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985, 102(1):29-36.
34. Girgis R.E., Mathai S.C. Pulmonary hypertension associated with chronic respiratory disease. Clin Chest Med 2007, 28(1):219-232.
35. Wilkinson M., Langhorne C.A., Heath D., et al. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med 1988, 66(249):65-85.
36. Penaloza D., Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007, 115(9):1132-1146.
37. Matsuoka S., Washko G.R., Yamashiro T., et al. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 2010, 181(3):218-225.
38. Falk J.A., Martin U.J., Scharf S., et al. Lung elastic recoil does not correlate with pulmonary hemodynamics in severe emphysema. Chest 2007, 132(5):1476-1484.
39. Shlobin O.A., Nathan S.D. Pulmonary hypertension secondary to interstitial lung disease. Expert Rev Respir Med 2011, 5(2):179-189.
40. Nathan S.D., Noble P.W., Tuder R.M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007, 175(9):875-880.
41. Tillie-Leblond I., Marquette C.H., Perez T., et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006, 144(6):390-396.
42. Rizkallah J., Man S.F., Sin D.D. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009, 135(3):786-793.
43. Swigris J.J., Olson A.L., Huie T.J., et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011, 140(5):1261-1266.
44. Panos R.J., Mortenson R.L., Niccoli S.A., et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990, 88(4):396-404.
45. Fessler H.E. Heart-lung interactions: applications in the critically ill. Eur Respir J 1997, 10(1):226-237.
46. Watz H., Waschki B., Meyer T., et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010, 138(1):32-38.
47. Buda A.J., Pinsky M.R., Ingels N.B., et al. Effect of intrathoracic pressure on left ventricular performance. N Engl J Med 1979, 301(9):453-459.
48. Macnee W. Right heart function in COPD. Semin Respir Crit Care Med 2010, 31(3):295-312.
49. Oswald-Mammosser M., Oswald T., Nyankiye E., et al. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis 1987, 71(5):419-429.
50. Tan R.T., Kuzo R., Goodman L.R., et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest 1998, 113(5):1250-1256.
51. Zisman D.A., Karlamangla A.S., Ross D.J., et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007, 132(3):773-779.
52. Steen V.D., Graham G., Conte C., et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35(7):765-770.
53. Nadrous H.F., Pellikka P.A., Krowka M.J., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005, 128(4):2393-2399.
54. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006, 61(1):68-74.
55. Gartman E.J., Blundin M., Klinger J.R., et al. Initial risk assessment for pulmonary hypertension in patients with COPD. Lung 2012, 190(1):83-89.
56. Mathai S.C., Hummers L.K., Champion H.C., et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009, 60(2):569-577.
57. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48(2):516-522.
58. Leuchte H.H., Neurohr C., Baumgartner R., et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004, 170(4):360-365.
59. Arena R., Guazzi M., Myers J., et al. Cardiopulmonary exercise testing in the assessment of pulmonary hypertension. Expert Rev Respir Med 2011, 5(2):281-293.
60. Holverda S., Bogaard H.J., Groepenhoff H., et al. Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension. Respiration 2008, 76(2):160-167.
61. Vonbank K., Funk G.C., Marzluf B., et al. Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD. Wien Klin Wochenschr 2008, 120(23-24):749-755.
62. Glaser S., Noga O., Koch B., et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 2009, 103(2):317-324.
63. Leuchte H.H., Baumgartner R.A., Nounou M.E., et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006, 173(7):744-750.
64. Inoue Y., Kawayama T., Iwanaga T., et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009, 48(7):503-512.
65. Holverda S., Rietema H., Westerhof N., et al. Stroke volume increase to exercise in chronic obstructive pulmonary disease is limited by increased pulmonary artery pressure. Heart 2009, 95(2):137-141.
66. Barr R.G., Bluemke D.A., Ahmed F.S., et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010, 362(3):217-227.
67. Gao Y., Du X., Liang L., et al. Evaluation of right ventricular function by 64-row CT in patients with chronic obstructive pulmonary disease and cor pulmonale. Eur J Radiol 2012, 81(2):345-353.
68. Burgess M.I., Bright-Thomas R. Usefulness of transcutaneous Doppler jugular venous echo to predict pulmonary hypertension in COPD patients. Eur Respir J 2002, 19(2):382-383.
69. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167(5):735-740.
70. Fisher M.R., Criner G.J., Fishman A.P., et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007, 30(5):914-921.
71. Forfia P.R., Fisher M.R., Mathai S.C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006, 174(9):1034-1041.
72. Mertens L.L., Friedberg M.K. Imaging the right ventricle-current state of the art. Nat Rev Cardiol 2010, 7(10):551-563.
73. Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172(2):189-194.
74. Egan T.M., Murray S., Bustami R.T., et al. Development of the new lung allocation system in the United States. Am J Transplant 2006, 6(5 Pt 2):1212-1227.
75. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980, 93(3):391-398.
76. Zielinski J., Tobiasz M., Hawrylkiewicz I., et al. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998, 113(1):65-70.
77. Crockett A.J., Cranston J.M., Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev 2001, 3. CD002883.
78. Kliment C.R., Oury T.D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 2010, 49(5):707-717.
79. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
80. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554.
81. Saito S., Miyamoto K., Nishimura M., et al. Effects of inhaled bronchodilators on pulmonary hemodynamics at rest and during exercise in patients with COPD. Chest 1999, 115(2):376-382.
82. Matthay R.A. Favorable cardiovascular effects of theophylline in COPD. Chest 1987, 92(Suppl 1):22S-26S.
83. Mols P., Huynh C.H., Dechamps P., et al. Dose dependency of aminophylline effects on hemodynamic and ventricular function in patients with chronic obstructive pulmonary disease. Chest 1993, 103(6):1725-1731.
84. Gluskowski J., Hawrylkiewicz I., Zych D., et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990, 3(4):403-407.
85. Benyounes B., Crestani B., Couvelard A., et al. Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X). Chest 1996, 110(1):284-286.
86. Raghu G., Collard H.R., Egan J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
87. Grunstein R.R., Stenlof K., Hedner J.A., et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007, 30(6):703-710.
88. Johansson K., Neovius M., Lagerros Y.T., et al. Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ 2009, 339:b4609.
89. Sugerman H.J., Baron P.L., Fairman R.P., et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988, 207(5):604-613.
90. Zohar Y., Talmi Y.P., Frenkel H., et al. Cardiac function in obstructive sleep apnea patients following uvulopalatopharyngoplasty. Otolaryngol Head Neck Surg 1992, 107(3):390-394.
91. Sajkov D., Wang T., Saunders N.A., et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002, 165(2):152-158.
92. Hoeper M.M., Barbera J.A., Channick R.N., et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S85-S96.
93. Vonbank K., Ziesche R., Higenbottam T.W., et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003, 58(4):289-293.
94. Roger N., Barbera J.A., Roca J., et al. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997, 156(3 Pt 1):800-806.
95. Blanco I., Gimeno E., Munoz P.A., et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010, 181(3):270-278.
96. Collard H.R., Anstrom K.J., Schwarz M.I., et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007, 131(3):897-899.
97. Zisman D.A., Schwarz M., Anstrom K.J., et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363(7):620-628.
98. Stolz D., Rasch H., Linka A., et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32(3):619-628.
99. Badesch D.B., Feldman J., Keogh A., et al. ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012, 30(2):93-99.
100. Naeije R., Melot C., Mols P., et al. Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Respir Dis 1982, 125(1):1-5.
101. Archer S.L., Mike D., Crow J., et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996, 109(3):750-755.
102. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360(9337):895-900.
103. Dernaika T.A., Beavin M., Kinasewitz G.T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010, 79(5):377-382.
104. Lee T.M., Chen C.C., Shen H.N., et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009, 116(6):497-505.
105. Reed R.M., Iacono A., DeFilippis A., et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD 2011, 8(2):96-102.
106. Kawut S.M., Bagiella E., Lederer D.J., et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011, 123(25):2985-2993.
107. Orens J.B., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25(7):745-755.
108. Fitton T.P., Kosowski T.R., Barreiro C.J., et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005, 24(9):1254-1259.
109. Criner G.J., Scharf S.M., Falk J.A., et al. Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. Am J Respir Crit Care Med 2007, 176(3):253-260.
110. Weitzenblum E., Hirth C., Ducolone A., et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36(10):752-758.
111. Oswald-Mammosser M., Weitzenblum E., Quoix E., et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995, 107(5):1193-1198.
112. Shorr A.F., Davies D.B., Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003, 124(3):922-928.
113. Baughman R.P., Engel P.J., Taylor L., et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010, 138(5):1078-1085.
114. Minai O.A., Ricaurte B., Kaw R., et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009, 104(9):1300-1306.
115. Barbera J.A., Roca J., Ferrer A., et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997, 10(6):1285-1291.
116. Weitzenblum E., Apprill M., Oswald M., et al. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest 1994, 105(5):1377-1382.
117. MacNee W., Wathen C.G., Flenley D.C., et al. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am Rev Respir Dis 1988, 137(6):1289-1295.